- Patients with histologically-confirmed metastatic or unresectable gastrointestinal
stromal tumor (GIST).
- Patients previously treated with imatinib mesylate.
- Patients who have not recovered from the acute toxic effects of previous
antineoplastic therapy or treatment with imatinib mesylate.
- Any tumor therapy for gastrointestinal stromal tumor (GIST) discontinued less than 4
weeks prior to starting study treatment. Imatinib mesylate discontinued less than 2
weeks prior to starting therapy.